Skip to main content
The Uromigos

The Uromigos

By The Uromigos
Broadcasting the latest developments in GU cancer
Listen on
Where to listen
Apple Podcasts Logo

Apple Podcasts

Breaker Logo

Breaker

Google Podcasts Logo

Google Podcasts

Pocket Casts Logo

Pocket Casts

RadioPublic Logo

RadioPublic

Spotify Logo

Spotify

Currently playing episode

Episode 10: COVID-19 and Renal Cancer: A Patient's Perspective

The Uromigos

1x
Episode 113: Radionucleotides in prostate cancer
Chris Sweeney and Silke Gillessen give their opinion of recent data. 
18:57
June 18, 2021
Episode 112: ASCO 2021 Enazlutamide +/- Radium-223
Silke Gillessen gives a safety update from this EORTC study focusing on fractures. 
11:03
June 18, 2021
Episode 112: Genomic classifier of high risk African American men with prostate cancer identifying a high-risk population
Kosj Yamoah (Moffitt Cancer Center) describes the work he presented at ASCO 2021.
20:57
June 10, 2021
Episode 111: The randomised phase 3 CANTATA in metastatic renal cancer
Nizar Tannir describes the results of this trial with a novel glutaminase inhibitor. 
29:03
June 8, 2021
Episode 110: PEACE1 - Triplet therapy in prostate cancer
Karim Fizazi describes the results of this randomised, potentially practice-changing trial. 
27:51
June 8, 2021
Episode 109: Adjuvant pembrolizumab in renal cancer
Toni Choueiri describes the KN564 study in detail.
30:46
June 7, 2021
Episode 108: Peter O'Donnell gives five year follow-up data on front line pembrolizumab in urothelial cancer
Tom and Peter continue to see things differently - has the data changed things? 
24:09
June 7, 2021
Episode 107: Neoadjuvant chemo/nivolumab as bladder sparing
Matt Galsky describes his Phase 2 study and gives a vision of the future.
16:48
June 7, 2021
Episode 106: Summary of the three bladder sparing neoadjuvant trials at ASCO 2021
Andrea Necchi gives a summary of the three abstracts. 
26:01
June 7, 2021
Episode 105: A Phase 2 study of novel immune combinations (ICOS) in bladder cancer
Arjun Balar discusses this and his neoadjuvant chemo/immune/RT trial.
19:39
June 7, 2021
Episode 104: Plenary Session 177lu-PSMA-617 in Prostate Cancer
Mike Morris does his stuff. 
30:17
June 6, 2021
Episode 103: Targeting the microbiome to increase the activity of immune therapy in renal cancer
Monty Pal describes a small randomised trial of ipi/nivo plus CMB588.
13:31
June 6, 2021
Episode 102: Adjuvant therapy in melanoma - how it will help inform the renal community
James Larkin describes learning from adjuvant immune checkpoint inhibitors in melanoma. 
29:05
May 28, 2021
Episode 101: The Uromigos Paper of the Month - Belzutifan in renal cancer
Eric Jonasch gives an overview of the recent Nature Medicine publication. 
26:60
May 26, 2021
Episode 100: The Uromigos 100th Podcast - Looking to the Future
Chris Sweeney, Kala Sridhar and David McDermott discuss the future. 
36:25
May 21, 2021
Episode 99: Navigating social media from a patients' perspective
Dena Battle is the co-founder and president of KCure and a passionate kidney cancer patient advocate. 
24:59
May 19, 2021
Episode 98: Bladder cancer from a patient perspective
Dr. Lydia Makaroff, Vice President of the World Bladder Cancer Patient Coalition, discusses key issues for bladder cancer. 
23:36
May 19, 2021
Episode 97: Sacituzumab Govitecan in Bladder Cancer
Petros Grivas discusses the recent accelerated approval and JCO paper data.
18:21
May 4, 2021
Episode 96: ODAC Bladder Cancer Accelerated Approval Meetings with Andrea Apolo
Andrea Apolo discusses highlights from the April 28th meeting. 
26:24
April 28, 2021
Episode 95: ODAC Overview and Bladder Accelerated Approval Meetings with Jorge Garcia
Jorge Garcia discusses the pembrolizumab and atezolizumab bladder cancer dangling accelerated approvals and the ODAC process
26:56
April 28, 2021
Episode 94: EIKCS Summary of Day 1
Samra Turajlic summarised the meetings and looks forward to Day 2...
24:40
April 23, 2021
Episode 93: The Uromigos Paper of the Month - A new risk classification for germ cell cancer
Silke Gillessen discusses the back to back JCO papers on this topic. 
23:50
April 14, 2021
Episode 92: Second line therapy in advanced RCC
Viktor Grünwald discusses treatment for progression of disease after front lines PD1 based therapy. 
27:31
April 9, 2021
Episode 91: The Uromigos Paper of the Month - Adjuvant atezolizumab in bladder cancer
Joaquim Bellmunt describes this study as well as adjuvant nivolumab and ctDNA in bladder cancer. 
29:05
March 26, 2021
Episode 90: The Uromigos Podcast with QOL Expert David Cella
Everything you wanted to know about quality of life assessment in cancer but were too afraid to ask. 
27:46
March 12, 2021
Episode 89: The Uromigos Paper of the Month - Pembrolizumab in clear cell and non-clear cell renal cancer
David McDermott describes these back to back JCO publications. 
28:15
March 4, 2021
Episode 88: Career Development in Academic Oncology Part 3 - Walter Stadler
In these podcasts, we explore academic career development with individuals in different stages of their career. 
23:15
February 26, 2021
Episode 87: Career Development in Academic Oncology Part 2 - Monty Pal
In these podcasts, we explore academic career development with individuals at different stages in their career. 
22:17
February 26, 2021
Episode 86: Career Development in Academic Oncology Part 1 - Moshe Ornstein
In these podcasts, we explore academic career development with individuals in different stages of their career. 
20:55
February 26, 2021
Episode 85: The CLEAR Trial - Toni Choueiri
Details of the study......
29:43
February 14, 2021
Episode 84: Prostate cancer highlights from ASCO #GU21 with Chris Sweeney
Chris explores the prostate cancer programme. 
17:24
February 13, 2021
Episode 83: Is cabozantinib the new standard of care in papillary renal cancer?
Monty Pal discusses his randomised phase 2 study in papillary renal cancer. 
21:54
February 13, 2021
Episode 82: Which is the best VEGF/immune combination for first line metastatic renal cancer?
Eric Jonash gives a thoughtful answer to this issue. 
24:41
February 13, 2021
Episode 81: Noah Hahn discusses front line cisplatin-ineligible PD-L1 data from 361 and 130
These new data are important as it is the setting where these agents are currently recommended, but we have not seen the data in this specific subset until now. 
21:22
February 13, 2021
Episode 80: Results for Darolutamide in non-metastatic CRPC - the Aramis trial
Neil Shore presents the impressive updates for the results of this trial. 
19:52
February 13, 2021
Episode 79: Adjuvant nivolumab in operable urothelial cancer
Matt Galski discusses this potentially practice-changing study. 
24:37
February 13, 2021
Episode 78: Enfortumab Vedotin Special: EV301 randomised trial and EV201 in urothelial cancer
Arjun Balar discusses these studies and the impact they will have. 
22:39
February 12, 2021
Episode 77: The Uromigos Paper of the Month - Nadofaragene for BCG unresponsive NMIBC
Stephen Boorjian outlines his recent Lancet oncology paper. Tom and Brian struggle to keep up. 
17:22
February 6, 2021
Episode 76: Tom Hutson discusses lenvatinib and everolimus
Discussion on lenvatinib and everolimus prior to the CLEAR trial presentation. 
23:52
January 22, 2021
Episode 75: The Uromigos meet APCCC - bone health and bone disease in prostate cancer with Bertrand Tombal
Silke, Chris and Bertrand discuss bone protective therapy and bone targeted therapy. 
25:48
January 14, 2021
Episode 74: The Uromigos meet APCCC Round 2: First line treatment - low vs high volume; chemo vs abi/enza
Nick James and Chris Sweeney debate this issue. Tom and Silke try to keep things on track. 
32:05
January 11, 2021
Episode 73: The Uromigos meet APCCC in a discussion on oligometastatic prostate cancer @APCCC_Lugano
Piet Ost, Chris Sweeney and Silke Gillessen discuss controversies around the management of oligometastatic prostate cancer. 
25:11
January 8, 2021
Episode 72: Uromigos Christmas Special - Renal cancer year in review
Laurence Albiges discusses renal cancer highlights from the year. 
24:25
December 21, 2020
Episode 71: Bladder Cancer Uromigos Christmas Special with Matt Galsky
Matt discusses the year in review, including first line and adjuvant immune therapy studies, ADCs and FGFR targeting are also discussed. 
24:58
December 18, 2020
Episode 70: The Uromigos Prostate Cancer Christmas Special with Chuck Ryan
A review of the year in prostate cancer with Chuck Ryan. 
25:57
December 11, 2020
Episode 69: Testis Cancer Christmas Special: 2020 year in review
Christian Kollmannsberger gets into the Christmas spirit by discussing highlights of 2020. 
25:17
December 9, 2020
Episode 68: Uromigos Paper of the Month - a molecular classification of renal cancer in Cancer Cell
Kim Rathmell discusses this paper, which divides clear cell renal cancer into seven relevant subgroups. Brian askes an interesting question at one point. 
26:25
December 8, 2020
Episode 67: The Third Uromigos Debate - PD1/VEGF vs PD1/CTLA4 for front line renal cancer
David McDermott and Brian Rini debate treatment options in front line renal cancer. It's hard to identify any winners from this podcast.
28:49
November 17, 2020
Episode 66: Uromigos Paper of the Month - Two papers in Nature Medicine on neoadjuvant immune combinations in bladder cancer
Pam Sharma and Michiel Van Der Heijden discuss neoadjuvant PD(L)1 + CTLA4 inhibition in urothelial cancer. 
30:49
November 9, 2020
Episode 65: Review of the International Kidney Cancer Symposium
Gretchen Vaughan, Kidney Cancer Association CEO, discusses the upcoming International Kidney Cancer Symposium meeting and KCA's grant program. Tom and Brian review some of the top abstracts. 
22:31
November 2, 2020
Episode 64: The Second Uromigos debate with Nobel Laureate Bill Kaelin on new biomarker vs new drugs in RCC
'New Drugs vs New Biomarkers' Bill Kaelin (Nobel Laureate) vs Tom Powles (keen cyclist), extend their discussion from KCRS20 in the 2nd Uromigos Debate. 
28:58
October 28, 2020
Episode 63: The First Uromigos Debate: front line immune therapy vs maintenance avelumab in bladder cancer
Dr. Peter O'Donnell and Prof. Tom Powles debate front line treatment options in urothelial cancer. 
21:19
October 9, 2020
Episode 62: James Eastham's Uromigos Paper of the Month - Prostatectomy +/- Neoadjuvant Chemo
A large randomised investigator-initiated Alliance study gives insight in to perioperative treatments for high risk prostate cancer. 
27:44
October 6, 2020
Episode 61: Nick James discusses the latest update of the STAMPEDE study
Nick gives us a quick summary of the STAMPEDE study and gives an overview of the latest data. 
17:17
September 21, 2020
Episode 60: Cora Sternberg discusses AMG 160 - a bispecific antibody in prostate cancer
AMG 160; a half-life extended (HLE) bispecific T-cell engager (BITE®) antibody construct is discussed as is the future of immune therapy in CRPC. 
14:58
September 21, 2020
Episode 59: Ipatercertib in biomarker positive castrate resistant prostate cancer
Chris Sweeney (last author) discusses the ATK inhibitor Ipatercertib in pTEN altered CRPC. A positive R3 trial in the ESMO plenary session. 
25:34
September 20, 2020
Episode 58: Brilliant ESMO discussant Richard Cathomas talks to Brian and Tom about the meaning of DANUBE and KN362
The group go into the detail of chemo immune combinations and what to do next. 
26:45
September 19, 2020
Episode 57: Toni Choueiri - cabo & nivo vs sunitinib in metastatic clear cell renal cancer
The group attempts to put the data into context with the other available combinations.
26:12
September 19, 2020
Episode 56: Matt Galsky and Tom Powles discuss ESMO 2020 immune therapy data in bladder cancer
The group try to get to the bottom of whether these data has made any difference in treatment and future plans. 
27:40
September 19, 2020
Episode 55: The Uromigos Paper of the Month - Cabozantinib in Bladder Cancer by Dr. Andrea Apolo
Andrea talks about her phase 2 trial which shows activity for Cabozantinib in urothelial cancer. 
23:26
August 31, 2020
Episode 54: Biomarkers in prostate cancer with Chris Sweeney
Some thought it would never come - the final podcast of the World Tour from Boston.
25:05
July 24, 2020
Episode 53: Still in Boston - biomarkers in bladder cancer
Tom, Brian and Chris Sweeney discuss the challenges of development of biomarkers for immune therapy in bladder cancer. 
18:44
July 24, 2020
Episode 52: The Final Stop - Boston: David McDermott discusses biomarkers in renal cancer in the era of immune therapy
Tom, David and Brian discuss biomarkers in renal cancer in the era of immune therapy.
20:01
July 24, 2020
Episode 51: The Uromigos World Tour is in Norway with Jan Oldenburg - discussing key topics in testis cancer
Jan Oldenburg from Norway discusses treatment choices for stage 1 testis cancer, the dilemma of high dose therapy for relapse and long term toxicity of chemotherapy. 
22:53
July 18, 2020
Episode 50: The Uromigos World Tour in London with renal cancer surgery
Axel Bex talks about small renal masses, robotic vs partial nephrectomy and surgery in metastatic disease. 
22:53
July 15, 2020
Episode 49: The Tour remains in Germany with Oliver Grimm and renal cancer
The World Tour stays in Germany to discuss the first line renal cancer (clear cell and non-clear cell) and clinical trials with Oliver Grimm. 
22:16
July 14, 2020
Episode 48: ...and then Germany - Jürgen Gschwend discusses cystectomy for urothelial cancer
Jürgen discusses German research and surgery for bladder cancer. The podcast ends abruptly - which was not his fault! 
20:38
July 10, 2020
Episode 46: The Uromigos World Tour in Spain discussing SOGUG and Renal Cancer with Cristina Suarez
Cristina Suarez discusses the success of clinical trials in Spain, and access to treatments. 
19:38
July 9, 2020
Episode 45: The Uromigos World Tour arrives in Japan
Yoshi Tomita explains treatment pathways and research in GU cancer in Japan. Brian explains why he likes Japan so much. 
20:30
July 3, 2020
Episode 44: The Uromigos World Tour in Australia - Talking with Ian Davis about prostate cancer and ANZUP
Ian Davis discusses why ANZUP has been so successful, and the EnzaMet study. An uninvited guest arrives towards the end. 
31:52
July 3, 2020
Episode 43: The Uromigos World Tour in Singapore with Ravi Kanesvaran
Ravi describes treatment pathways and research for Southeast Asia in GU cancer. 
18:21
June 29, 2020
Episode 42: The Uromigos in Argentina
Juan Sade discusses research, treatment pathways in GU cancer, steak and red wine in Argentina. 
12:09
June 28, 2020
Episode 41: The Uromigos World Tour lands in Brazil - Fernando Maluf talks about prostate cancer and recent research in Brazil
The tour lands in sunny Brazil with a trip to a Japanese restaurant and a discussion about research and prostate cancer. 
24:04
June 25, 2020
Episode 40: The Uromigos World Tour moves to France - Bernard Escudier discusses 2nd line therapy in renal cancer and Tivozanib
The Uromigos World Tour moves to Paris. Treatment for tumours that progress after first line immunetherapy is discussed. The role of Tivozanib is a focus for the dialogue. 
20:03
June 22, 2020
Episode 39: The Uromigos World Tour - Renal Cancer and IMDC Risk with Danny Heng in Calgary
Danny discusses Italian food and the past, present and future of the IMDC prognostic score. 
20:18
June 18, 2020
Episode 38: The Uromigos Virtual World Tour - starting in Vancouver with Atezolizumab in NMIBC
Peter Black talks about his recent BCG refractory NMIBC ASCO presentation and its implications for the field. 
20:22
June 16, 2020
Episode 37: Regoratinib (FGFR inhibitor) and Atezolizumab in UC with Jonathan Rosenberg
Everything you wanted to know about FGFR inhibition but were afraid to ask. 
18:12
June 1, 2020
Episode 36: Dr. Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations
 Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations
20:59
June 1, 2020
Episode 35: Maintenance Avelumab in Bladder Cancer (LBA1)
Dr. Kala Sridhar, Professor Tom Powles and Dr. Brian Rini discuss the data presented at ASCO. 
17:42
May 31, 2020
Episode 34: Savolitinib in Renal Papillary Cancer - A Major Breakthrough?
Dr. Toni Choueiri discusses the results of this study, which appears to show a survival signal, but it is difficult to interpret. 
20:41
May 30, 2020
Episode 33: Adjuvant Atezolizumab in Urothelial Cancer
Joaquim Bellmunt explains a bit about why this trial was not successful and what it means for the field. 
19:59
May 29, 2020
Episode 32: A Phase 2 Study of PSMA PET in Prostate Cancer with Thomas Hope from ASCO 2020
Thomas Hope is quizzed on the results of his study presented at ASCO20.
24:09
May 29, 2020
Episode 31: A Phase 2 Study of Nivolumab with the Addition of Ipilimumab Upon Progression in Renal Cancer
Mike Atkins describes the results of this study which helps shed light on the role of ipilimumab and nivolumab in this disease. 
25:18
May 29, 2020
Episode 30: Update on Axitinib plus Pembrolizumab in Renal Cancer (KEYNOTE 426)
Betsy Plimack discusses the updated data with a minimum of 23 months' follow up. Dr. Brian Rini and Professor Tom Powles asks what it adds. 
20:04
May 29, 2020
Episode 29: PSMA PET at ASCO 2020 with Mike Morris
Mike Morris presents the findings in his prospective study. 
23:48
May 29, 2020
Episode 28: Targeting VHL Syndrome Renal Cancer with a HIF Inhibitor - A Game Changer
Eric Jonasch discusses his ASCO presentation, which shows significant activity of HIF targeting in renal cancer patients with VHL syndrome. 
13:31
May 29, 2020
Episode 27: COVID-19 in > 1000 Cancer Patients with Jeremy Warner (CCC-19)
Jeremy Warner summarises the recent Lancet paper describing the outcome of cancer patients with COVID-19. 
21:45
May 29, 2020
Episode 26: Joaquim Bellmunt and Muscle Invasive Bladder Cancer prior to ASCO 2020
Joaquim Bellmunt talks about management of muscle invasive bladder cancer prior to the Atezolizumab adjuvant data at ASCO20. 
22:23
May 19, 2020
Episode 25: Dr. Tian Zhang discusses first line treatment for renal cancer and the PDIGREE Trial
Dr. Tian Zhang discusses first line treatment for renal cancer and the PDIGREE Trial.
14:48
May 19, 2020
Episode 24: A Study of COVID-19 in Lung Cancer Shows High Mortality
Marina Garassino and Leora Horn discuss their AACR study of COVID-19 in lung cancer.
19:51
April 28, 2020
Episode 23: Atezolizumab and Enzalutamide versus Enzalutamide Prostate Cancer
Chris Sweeney explains why the trial was negative and answers some of the questions.
22:36
April 28, 2020
Episode 22: COVID-19 and Cardiovascular Disease
Kaushik Amancherla and Javid Moslehi discuss the link of COVID-19 and cardiovascular disease. Professor Tom Powles and Dr. Brian Rini struggle to keep up.
18:28
April 22, 2020
Episode 21: Treating cancer patients over the next year in the era of COVID-19
The Uromigos struggle to describe what cancer care looks like in three months’ time during the COVID-19 pandemic.
12:34
April 15, 2020
Episode 20: Treating GU Cancer Patients with acute COVID-19 Infection
The Uromigos can’t agree on how to approach COVID-infected GU cancer patients who need systematic treatment.
13:08
April 15, 2020
Episode 19: Professor Monty Pal discusses the treatment of non-clear cell renal cancer
Professor Monty Pal discusses non-clear cell renal cancer while Dr. Brian Rini gets irritated by background interruptions. 
18:17
April 15, 2020
Episode 18: COVID-19: Addressing Renal Cancer Patients’ Concerns
Dena Battle presents a 500-patient survey on issues around COVID-19. Professor Tom Powles and Dr. Brian Rini attempt to address the issues raised.
24:47
April 6, 2020
Episode 17: Dr. Toni Choueiri discusses cancer trials and meetings during COVID-19
Professor Tom Powles, Dr. Brian Rini and Dr. Toni Choueiri discuss the evolving landscape in Boston, and meetings such as ASCO and ESMO in 2020.
21:33
April 2, 2020
Episode 16: Treatments and Trials for COVID-19
Professor Nick Mark discusses the latest data on drug treatments and trials for COVID-19.
25:31
March 31, 2020
Episode 15: COVID-19 and Bladder Cancer Surgery
The Uromigos discuss the practicalities in surgery for bladder cancer in the era of COVID-19 with Betsy Plimack (Fox Chase Cancer Center, Philadelphia)
14:52
March 28, 2020
Episode 14: A Discussion about Tocilizumab and COVID-19 with Dr. Nick Mark from Seattle
Dr. Brian Rini and Professor Tom Powles discuss the data and ongoing studies with the IL-6 antibody tocilizumab.
15:04
March 24, 2020
Episode 13: COVID-19 and Hydroxychloroquinine Existing Data and Ongoing Trials
Dr. David Boulware discusses existing data and ongoing prophylaxis studies.
18:45
March 23, 2020
Episode 12: COVID-19 in Cancer Patients - The Seattle Experience
A discussion with doctors from the Fred Hutchinson Cancer Center in Seattle about COVID-19.
26:19
March 20, 2020
Episode 11: COVID-19 and Immune Checkpoint Inhibitors for the Treatment of Cancer
Chuck Drake and Doug Johnson discuss possible risk benefits of immune checkpoint inhibitors during the COVID-19 pandemic. 
17:44
March 16, 2020
Episode 10: COVID-19 and Renal Cancer: A Patient's Perspective
Dena Battle (President, KCCure) asks key patient-focused questions about kidney cancer management during the COVID-19 pandemic. 
27:10
March 16, 2020
Episode 9: COVID-19 and Cancer: An International Perspective
Five members of the groups from Europe and North America discuss the current situation for cancer patients. 
21:58
March 16, 2020
Episode 8: COVID-19 and Cancer Patients
Professor Tom Powles and Dr. Brian Rini discuss the virus with an expert, Ronan Breen. 
21:54
March 13, 2020
Episode 7: The First Uromigos Prostate Cancer Podcast
Silke Gillessen and Chris Sweeney discuss how data from recent ESMO and GU ASCO meetings has changed the way they treat prostate cancer. 
25:32
February 27, 2020
Episode 6: Urothelial Cancer Highlights from ASCO GU 2020
In this episode, Professor Tom Powles and Dr. Brian Rini talk to Dr. Kala Sridhar about key developments in urothelial cancer presented at ASCO GU 2020. 
20:09
February 26, 2020
Episode 5: Renal Highlights from ASCO GU 2020
Professor Tom Powles and Dr. Brian Rini broadcast from ASCO GU 2020, San Francisco. 
10:14
February 24, 2020
Episode 4: Treatment Choices in Front Line Advanced Renal Cancer
Dr. Brian Rini and Professor Tom Powles ask David McDermott about how he chooses between ipilimumab/nivolumab or axitinib/pebrolizumab intreatment options
26:40
February 11, 2020
Episode 3: Pembrolizumab in Non-Muscle Invasive Bladder Cancer
Guests Dr. Arjun Balar and Professor Seth Lerner give an overview of the recent FDA approval of pembrolizumab in this indication to Professor Tom Powles and Dr. Brian Rini.
33:03
February 11, 2020
Episode 2: The Current role of IO in Front-line Advanced Urothelial Cancer
Matthew Galski and Petros Grivas engage in a discussion with Professor Tom Powles and Dr. Brian Rini about IMVIGOR130.
30:18
February 11, 2020
Episode 1: Introduction to Uromigos Podcasts
Professor Tom Powles and Dr. Brian Rini discuss the purpose of the podcasts and how to complain if you don’t like them
03:21
February 11, 2020